LA­VA Ther­a­peu­tics winds down bis­pe­cif­ic tri­al; Blue Wa­ter buys six mar­ket­ed drugs for $8.5M

Bis­pe­cif­ic de­vel­op­er LA­VA Ther­a­peu­tics is cut­ting a tri­al for a can­di­date tar­get­ing hema­to­log­i­cal ma­lig­nan­cies af­ter re­view­ing the cur­rent com­pet­i­tive land­scape, choos­ing in­stead to dou­ble down …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER